Deadly Drug-Resistant Fungus Now Confirmed in 23 States

A drug-resistant and often fatal fungus is spreading across the U.S. despite intense containment efforts.

A quiet but dangerous threat is expanding through American healthcare facilities, putting some of the most vulnerable patients at risk. The spread of this drug-resistant "superbug" highlights the growing challenge of combating antimicrobial-resistant pathogens in clinical settings.

WHAT HAPPENED

The Centers for Disease Control and Prevention (CDC) has confirmed that Candida auris, a deadly and drug-resistant fungus, has now spread to 23 U.S. states. First detected in the United States in 2016, the pathogen has proven notoriously difficult to eliminate. Despite intense containment efforts by public health officials and hospital staff, new data reveals that the fungus is once again on the move.

The fungus primarily spreads in healthcare facilities, such as hospitals and long-term nursing homes. It colonizes the skin of patients and can survive on surfaces like bed rails, medical equipment, and countertops for long periods, even after standard cleaning. While healthy individuals typically defeat the fungus naturally without falling ill, it poses an extreme danger to patients with weakened immune systems or those using invasive medical devices like ventilators or catheters.

In clinical settings, the consequences of an infection can be devastating. Mortality rates for patients who develop invasive infections can reach as high as 60%. Because certain strains of Candida auris are resistant to all three major classes of antifungal medications, doctors are often left with very few treatment options.

Key Facts & Numbers

• 23 states: The number of U.S. states where the CDC has confirmed cases of Candida auris.
• 60%: The potential mortality rate for infected patients in clinical settings.
• 2016: The year the fungal pathogen was first detected in the United States.
• Immunocompromised: The patient population facing the highest risk of severe or fatal infections.
• Surface survival: The fungus can persist on healthcare surfaces for long periods, resisting standard disinfectants.

WHY IT MATTERS

The rise of Candida auris represents a serious challenge to modern medicine. It is classified as an urgent antimicrobial threat because of its ability to resist standard treatments. When a pathogen becomes resistant to first-line drugs, healthcare providers must rely on stronger, more toxic, or less effective alternatives. In the worst-case scenarios, patients are left with no viable treatment options at all.

This superbug does not typically threaten the general public. However, for patients already battling severe illnesses in hospitals or nursing homes, the introduction of Candida auris can be a death sentence. The ease with which the fungus spreads from person to person and surface to surface makes outbreaks in closed medical environments incredibly difficult to control.

WHAT HAPPENS NEXT

To combat the spread, healthcare facilities are increasingly adopting enhanced barrier precautions. These measures require medical staff to wear fresh gowns and gloves when performing high-contact care for residents who are colonized or infected with the superbug.

Hospitals are also shifting their screening protocols, testing patients upon admission to identify carriers before they can transmit the fungus to others. Meanwhile, researchers and public health agencies are working to develop new, more effective antifungal treatments and stronger hospital-grade disinfectants capable of eradicating the resilient yeast from clinical environments.

WHAT WE STILL DON'T KNOW

1. Which specific states are currently experiencing the fastest rise in new Candida auris cases?
2. Will the fungus develop widespread resistance to the remaining advanced antifungal therapies that are currently used as a last resort?
3. How can healthcare facilities completely eliminate the pathogen from surfaces when standard cleaning methods fail?

SOURCE NOTE

This story draws on reporting from The Hill.